Open Actively Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

About

Brief Summary

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Primary Purpose
Treatment
Study Type
Interventional
Phase
Early Phase 1

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
30 Years
Maximum Age
65 Years

Inclusion Criteria:

  • Patient signed informed consent.
  • Age 30-65
  • Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
  • Intent to maintain current MS disease modifying treatment through the trial duration

Exclusion Criteria:

  • Clinical relapse in prior 12 months
  • New T2 lesion or gadolinium enhancing lesion in prior 12 months
  • Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
  • Changes in disease modifying therapy in prior three months
  • Plans to change current disease modifying therapy
  • Contraindication to MRI, inability to tolerate MRI
  • Use of metformin for any other indication
  • Renal dysfunction (GFR < 60)
  • Hepatic dysfunction (AST or ALT > 1.5 x upper limit of normal)
  • B12 deficiency
  • Prior poor reaction to metformin
  • Congestive heart failure
  • Alcohol abuse
  • Metabolic acidosis
  • Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
  • Concomitant use of drugs with drug-drug interactions with metformin
  • Previous adverse effect with metformin treatment

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-000020
Category
Neurology
Principal Investigator
Contact
Michael Montag
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05349474
For detailed technical eligibility, visit ClinicalTrials.gov.